BNGO Bionano Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BNGO

Price (delayed)

$1.7

Market cap

$20.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.02

Enterprise value

$22.49M

?
Relative Growth: Rel. Growth: 68
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 28

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to ...

Highlights
The EPS has soared by 93% YoY and by 31% QoQ
Bionano Genomics's debt has plunged by 66% YoY and by 61% from the previous quarter
BNGO's equity is down by 30% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.bionanogenomics.com
Peers: RVTY QTRX PRPO MTD

Key stats

What are the main financial stats of BNGO

BNGO stock price

How has the Bionano Genomics stock price performed over time
Intraday
-6.59%
1 week
12.58%
1 month
41.67%
1 year
1.19%
YTD
11.11%
QTD
50.44%

Financial performance

How have Bionano Genomics's revenue and profit performed over time
Revenue
$30.18M
Gross profit
$14.34M
Operating income
-$32.19M
Net income
-$32.16M
Gross margin
47.5%
Net margin
-106.6%
Bionano Genomics's net margin has soared by 61% YoY and by 3% from the previous quarter
The operating margin has surged by 59% year-on-year and by 6% since the previous quarter
The company's net income has surged by 57% YoY
BNGO's operating income has soared by 55% YoY

Price vs fundamentals

How does BNGO's price correlate with its fundamentals

Growth

What is Bionano Genomics's growth rate over time

Valuation

What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.62
P/S
0.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.75
The EPS has soared by 93% YoY and by 31% QoQ
BNGO's price to book (P/B) is 120% higher than its last 4 quarters average of 0.3 but 45% lower than its 5-year quarterly average of 1.2
BNGO's equity is down by 30% YoY and by 16% from the previous quarter
The P/S is 95% below the 5-year quarterly average of 13.1 but 75% above the last 4 quarters average of 0.4
Bionano Genomics's revenue has increased by 10% YoY and by 5% QoQ

Efficiency

How efficient is Bionano Genomics business performance
The ROS has soared by 61% YoY and by 3% QoQ
Bionano Genomics's ROIC has soared by 53% YoY but it has decreased by 14% from the previous quarter
Bionano Genomics's return on equity has surged by 53% YoY but it has decreased by 10% QoQ
Bionano Genomics's return on assets has increased by 48% YoY but it has decreased by 13% QoQ

Dividends

What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BNGO.

Financial health

How did Bionano Genomics financials performed over time
BNGO's total assets is 198% greater than its total liabilities
The total liabilities has declined by 48% year-on-year and by 42% since the previous quarter
BNGO's current ratio is up by 41% year-on-year and by 35% since the previous quarter
Bionano Genomics's debt is 79% less than its equity
Bionano Genomics's debt has plunged by 66% YoY and by 61% from the previous quarter
The debt to equity has dropped by 53% since the previous quarter and by 51% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.